You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The sequencing company reported preliminary fourth quarter revenues of $27 million and said it currently has $318 million in cash and investments.
Exact Sciences discussed new Cologuard data; Danaher reviewed Cepheid's 2020 performance; and NanoString talked about forthcoming spatial biology products.
The firm plans to begin its OTC efforts with a COVID antigen test but also sees potential in migrating other infectious disease tests.
Qiagen's CEO discussed the company's focus on specific growth drivers, while Invitae's CEO talked about pandemic-related challenges in its genetic testing business.
Last year, the company processed more than 1 million tests, most of them for its reproductive health business, but interest in Prospera and Signatera is growing.
Hologic said the acquisition of Biotheranostics will give it a company that operates in markets that are adjacent and complementary to its own.
Among firms presenting on the first day, 10x Genomics revealed it is developing a new high-throughput Chromium instrument, and Guardant plans to launch a comprehensive tissue sequencing assay.
The firm also provided preliminary revenues of $950 million for Q4 and reinstated guidance of $3.79 billion to $3.88 billion for 2021.
The company anticipates total revenues of $3.9 billion for 2020, including $1 billion from its COVID-19-related business.
The GenomeWeb Index fell 2 percent, outperforming the Nasdaq Biotechnology Index but doing worse than the Dow Jones and the Nasdaq.
The New York Times reports that Cedars-Sinai researchers have uncovered a new strain of SARS-CoV-2 in Southern California.
The Financial Times reports the US bolstering its ability to track SARS-CoV-2 alterations.
In Nucleic Acids Research this week: pan-cancer atlas focus on miRNA biogenesis mutations, methylation analysis of pig skeletal muscles, and more.
President-elect Joe Biden has nominated Eric Lander to serve as director of the Office of Science and Technology Policy, the Associated Press says.